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Summary
While proteasome inhibition is a validated therapeutic approach for multi-
ple myeloma (MM), inhibition of individual constitutive proteasome
(c20S) and immunoproteasome (i20S) subunits has not been fully explored
owing to a lack of effective tools. We utilized the novel proteasome consti-
tutive/immunoproteasome subunit enzyme-linked immunosorbent (Pro-
CISE) assay to quantify proteasome subunit occupancy in samples from
five phase I/II and II trials before and after treatment with the proteasome
inhibitor carfilzomib. Following the first carfilzomib dose (15–56 mg/m2),
dose-dependent inhibition of c20S and i20S chymotrypsin-like active sites
was observed [whole blood: ≥67%; peripheral blood mononuclear cells
(PBMCs): ≥75%]. A similar inhibition profile was observed in bone
marrow–derived CD138+ tumour cells. Carfilzomib-induced proteasome
inhibition was durable, with minimal recovery in PBMCs after 24 h but
near-complete recovery between cycles. Importantly, the ProCISE assay can
be used to quantify occupancy of individual c20S and i20S subunits. We
observed a relationship between MM patient response (n = 29), carfilzomib
dose and occupancy of multiple i20S subunits, where greater occupancy
was associated with an increased likelihood of achieving a clinical response
at higher doses. ProCISE represents a new tool for measuring proteasome
inhibitor activity in clinical trials and relating drug action to patient
outcomes.
Keywords: molecular analysis, multiple myeloma, myeloma therapy,
pharmacology, trials.
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The 26S proteasome is a ubiquitously expressed protein com-
plex responsible for the homeostatic control of protein turn-
over and regulated degradation of proteins involved in most
cellular functions (Wilk & Orlowski, 1983; Coux et al, 1996;
Ciechanover, 2012). Each proteasome has a 20S core, each
containing two copies of three distinct proteolytic enzymes.
The proteasome exists in two forms: the constitutive protea-
some (c20S), expressed ubiquitously throughout the body,
and the immunoproteasome (i20S), expressed primarily in
haematopoietic cells or in cytokine-exposed non-haemato-
poietic cells (Martinez & Monaco 1991; Glynne et al, 1991,
Nandi et al, 1996). In the c20S, proteolytic activities are
encoded in the b5, b1 and b2 subunits and are characterized
on the basis of substrate specificity as chymotrypsin-like
(CT-L), caspase-like and trypsin-like, respectively. In the
i20S, low-molecular mass polypeptide 7 (LMP7), LMP2 and
multicatalytic endopeptidase complex-like 1 (MECL1) replace
b5, b1 and b2, respectively.
Approval of the dipeptide boronic acid proteasome inhibi-
tor, bortezomib, for the treatment of relapsed multiple mye-
loma (MM; Richardson et al, 2005) and relapsed or
refractory mantle cell lymphoma (Fisher et al, 2006) has
spurred the development of other agents that target protea-
some activity (Bennett & Kirk, 2008; Dick & Fleming, 2010;
Kuhn et al, 2011). These agents vary from targeting individ-
ual active sites to targeting all three catalytic activities (Chau-
han et al, 2005; Muchamuel et al, 2009). Carfilzomib, a
tetrapeptide epoxyketone proteasome inhibitor, has recently
been approved in the US for the treatment of relapsed and
refractory MM (Kuhn et al, 2007; Jain et al, 2011). While
both carfilzomib and bortezomib primarily target the CT-L
activity of the c20S and i20S, carfilzomib displays greater
specificity than bortezomib for CT-L activity relative to cas-
pase-like and trypsin-like activities (Demo et al, 2007).
Accurate and relevant markers to monitor pharmacody-
namics are important in the development of targeted agents
for cancer, in which narrow therapeutic margins may limit
drug effectiveness (Kummar et al, 2010; Yap et al, 2010).
Ideally, direct measurement of target inhibition in malignant
cells should be related to patient outcome. This approach is
challenging given the complexity of the target (particularly
multi-subunit intracellular protein complexes), the need for
serial sampling, and the current lack of ready access to
tumour cells. Instead, surrogate tissues (e.g. cells isolated
from blood) and/or markers (e.g. changes in downstream
signalling pathways) are used to approximate the clinical
profile of an agent. This method may result in either equivo-
cal results or the incorporation of potentially suboptimal
dosing strategies into later clinical trials.
The standard method for determining proteasome inhibi-
tion uses biochemical substrates, such as Leu-Leu-Val-Tyr-7-
amino-4-methylcoumarin (LLVY-AMC) for determining
CT-L activity (Lightcap et al, 2000); however, this approach
cannot differentiate between c20S and i20S activity. MM cells
express both proteasome types, and the role of individual
subunits in the anti-tumour effect of clinically relevant pro-
teasome inhibitors remains an area of active research (Kuhn
et al, 2009; Parlati et al, 2009; Wehenkel et al, 2012). Mean-
while, the role of the non–CT-L active sites and their inhibi-
tion by proteasome inhibitors remain poorly understood,
mainly due to a lack of suitable substrates for measuring
enzymatic activity. Substrates for LMP2 and MECL1 are
poorly defined and, similar to LLVY-AMC, do not differenti-
ate between immunoproteasome subunit activity and the
corresponding constitutive proteasome subunits (Groettrup
et al, 2010). Studies utilizing inhibitors that specifically target
the caspase-like or trypsin-like active sites suggest that inhibi-
tion of non–CT-L active sites alone may sensitize cancer cells
to CT-L inhibition but are not sufficient to induce cytotoxic-
ity (Britton et al, 2009; Mirabella et al, 2011). Other assess-
ment tools are needed to fully characterize the role of c20S
and i20S active sites in the anti-cancer activity of proteasome
inhibitors. Considering these limitations, we developed the
proteasome constitutive/immunoproteasome subunit
enzyme-linked immunosorbent (ProCISE) assay to measure
the amounts and occupancy of proteasome active sites in
samples with heterogeneous proteasome composition (Parlati
et al, 2009). We previously reported the use of the ProCISE
assay in quantifying c20S and i20S subunit levels in primary
cells and cell lines derived from haematopoietic and solid
tumours (ST) (Parlati et al, 2009). Herein, we present the
first clinical application of ProCISE, demonstrating its utility
in determining the level of occupancy of all six proteasome
active sites in samples derived from MM and ST patients




Proteasome active site-binding probe (PABP) (Bennett et al,
2006) and carfilzomib (Smyth & Laidig, 2006) were synthe-
sized as previously described (Smyth & Laidig, 2006). The
fluorogenic substrate succinyl-LLVY-AMC and human c20S
and i20S were purchased from Boston Biochem (Boston,
MA, USA). Human whole blood and peripheral blood
mononuclear cell (PBMC)-enriched leukapheresis-derived
samples from healthy volunteers were purchased from All-
Cells (Berkeley, CA, USA). Monoclonal antibodies specific
for b1, b2, LMP7 and LMP2 were purchased from Enzo Life
Sciences (Farmingdale, NY, USA). Antibodies specific to
MECL1 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). A rabbit polyclonal anti-b5-antibody
was generated as previously described (Muchamuel et al,
2009). Horseradish peroxidase (HRP)–conjugated goat anti-
rabbit and goat anti-mouse were purchased from Jackson
ImmunoResearch (West Grove, PA, USA). HRP-conjugated
rabbit anti-goat was purchased from Invitrogen (Carlsbad,
CA, USA).
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Sample collection
Samples for analysis were derived from phase I/II and phase
II trials (Table I). Trial details can be found in the Supple-
mentary Information. Patients received carfilzomib as an
intravenous infusion over 2–10 min or, as in the case of PX-
171-007, over 30 min on days 1, 2, 8, 9, 15 and 16 of a 28-
day cycle at doses from 15 to 56 mg/m2.
In PX-171-003-A0/A1, PX-171-004 and PX-171-005, bone
marrow samples were collected during screening and on day
2 of cycle 1 (approximately 4 h post-dose). In PX-171-005,
PX-171-006 and PX-171-007, whole blood and isolated
PBMC samples were collected prior to dosing and 1 h post-
dose on days 1, 2 and 8 of cycle 1 and on day 1 of cycle 2
(no samples were collected on days 2 or 8 in cycle 1 for
patients with ST receiving carfilzomib over 2–10 min). All
samples were obtained after informed consent was given and
in accordance with the Helsinki Declaration.
Sample preparation
Bone marrow aspirates were enriched for CD138+ tumour
cells via immunomagnetic bead separation (RoboSep, Stem
Cell Technologies, Vancouver, Canada) as per the manufac-
turer’s protocol. Cells were lysed in lysis buffer (20 mM
Tris pH 8∙0, 5 mM ethylenediaminetetraacetic acid, EDTA)
and cleared of cellular debris by centrifugation prior to
analysis.
CT-L activity assay
CT-L activity using succinyl-LLVY-AMC was determined as
previously described (Lightcap et al, 2000; Demo et al,
2007). Protocol modifications for the current study included a
blood quality control (QC) matrix, generation of an
aminomethylcoumarin standard curve and QC samples.
Details are provided in the Supplementary Information.
ProCISE assay
We previously published the methodology of the ProCISE
assay for evaluation of samples from primary cells and tumour
cell lines (Parlati et al, 2009). The clinical application of the
ProCISE assay involves, in brief, the following steps: (i) incu-
bation of PABP with whole blood, PBMC or bone marrow
lysates; (ii) denaturation with 5∙6 M guanidine hydrochloride;
(iii) addition of streptavidin-coated beads; (iv) extensive bead
washing; (v) addition of proteasome subunit-specific primary
antibody followed by a secondary HRP-conjugated antibody;
and (vi) luminescence-based detection. Additional details on
the clinical application of the ProCISE assay can be found in
the Supplementary Information section.
Statistical analysis
One-tailed Welch–Satterthwaite t-tests, or fixed, or mixed-
effects analysis of variance models followed by Tukey’s
Table I. Clinical Samples used for Pharmacodynamic Analysis.
Blood and PBMC pharmacodynamic samples from MM patients*




II 31 15/20 (N = 31) –
PX-171-006
(NCT00603447)
Ib/II 16 15 only (n = 8)




I/II 24 20/36 (n = 3)
20/45 (n = 3)
20/56 (n = 19)
Bone marrow pharmacodynamic samples from MM patients‡
Trial† Phase N 2- to 10-min infusion dose (mg/m2) 30-min infusion dose (mg/m2)
PX-171-003-A0 and -A1
(NCT00511238)
II 7 20 only (N = 7;




II 11 20 only (N = 11;




II 15 Dose N/A (MM, N = 15; predose, n = 15;
C1D2, n = 0)
—
Blood and PBMC pharmacodynamic samples from ST patients*
PX-171-007
(NCT00531284)
I/II 36 20 only (n = 3)
20/27 (n = 3)
20/36 (n = 18)
20/45 (n = 2)
36 only (n = 6)
45 only (n = 6)
C, cycle; D, day; MM, multiple myeloma; N/A, not applicable; PBMC, peripheral blood mononuclear cell; ST, solid tumour.
*cycle 1, multiple days, and cycle 2, day 1 only.
†Blood and/or bone marrow aspirates were collected from patients in five clinical trials prior to and after carfilzomib treatment and at the doses
listed. Samples were analysed for proteasome activity and subunit occupancy as described in Fig 1.
‡Predose and C1, D2 only.
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studentized range post-hoc tests were used, as appropriate, to
determine statistically significant differences. The presence of
a linear trend was tested using an F-test for linear contrast.
Statistical analyses were performed using GraphPad Prism
(version 5.03; GraphPad Prism Software Inc., San Diego, CA,
USA) or SAS software (version 9.1.3; SAS Institute, Inc.,
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Results
ProCISE clinical validation
ProCISE quantitatively measures the levels of proteasome
subunit active sites within cell lysates via the addition of a
biotinylated probe that covalently binds to all active sites.
Probe-bound active sites are captured on streptavidin-
sepharose beads and quantified with subunit-specific anti-
bodies compared with a standard curve of purified protea-
somes (Fig 1A). We determined that ProCISE accurately
measures c20S and i20S subunits within a large dynamic
range (2–167% of c20S subunits and 3–250% of i20S sub-
units found within typical whole blood and PBMC sam-
ples, respectively; Table SI). In addition, when known
concentrations of c20S and i20S were spiked into whole
blood or PBMC samples, respectively, we observed good
correlation between the measured and expected values
(Figure S1).
To validate ProCISE as a measure of drug activity, we
treated whole blood for 1 hwith varying concentrations of
carfilzomib and analysed both whole blood and isolated
PBMCs (Figure S2). The ex vivo dose response of carfil-
zomib-mediated b5 and LMP7 occupancy measured by Pro-
CISE mirrored that of the enzymatic activity assessed using
LLVY-AMC in the same samples. Carfilzomib showed more
than 10-fold selectivity for CT-L subunits relative to other
c20S and i20S subunits, findings that were similar to previ-
ously reported results from purified proteasomes (Demo
et al, 2007). Finally, baseline levels of proteasome active sites
from MM and ST patient samples collected from multiple
studies were analysed by ProCISE (Fig 1B). Stoichiometric
amounts of the c20S subunits and the i20S subunits were
present in whole blood and PBMCs, respectively,
independent of tumour type. Additionally, levels of CT-L
activity inhibition and subunit occupancy in patients receiv-
ing carfilzomib were similar using the LLVY-AMC or Pro-
CISE assays in whole blood or PBMCs, suggesting that
measurement of subunit occupancy accurately reflects prote-
olytic activity (Fig 1C; Table SII). Taken together, these data
validate ProCISE for the quantitative measurement of protea-
some inhibition, active site occupancy and levels of active
site subunits in patient samples.
Inhibition of proteasome subunits by carfilzomib in
patients
Carfilzomib has demonstrated anti-tumour activity in
patients with MM at doses ranging from 15 to 56 mg/m2
(Siegel et al, 2012; Vij et al, 2012a,b; Badros et al, 2013;
Papadopoulos et al, 2013, 2015). In phase I and II trials,
only the LLVY-AMC assay was used in a limited number of
patient samples to measure CT-L activity alone (O’Connor
et al, 2009; Badros et al, 2013; Niesvizky et al, 2013; Papado-
poulos et al, 2013). To obtain the full active-site inhibition
profile of carfilzomib, we utilized ProCISE to quantify active
site activity and occupancy in whole blood and PBMC sam-
ples from patients in multiple studies (n = 41 ST and
n = 73 MM) 1 h after the first dose of carfilzomib (15–
45 mg/m2) was administered. In patients receiving 15 or
20 mg/m2 of carfilzomib as a 2- to 10-min infusion, rates of
inhibition of b5 and LMP7 occupancy in whole blood and
PBMC samples were 67–74% and 77–80%, respectively (see
Fig 1C). At 20 mg/m2, no significant difference in the level
of proteasome inhibition was detected between patients
receiving a 2- to 10-min infusion and those receiving a 30-
min infusion. Inhibition of the other i20S subunits (MECL1
and LMP2) was also observed in PBMCs at doses of 15 and
Fig 1. Carfilzomib administration results in potent inhibition of multiple proteasome subunits. (A) ProCISE assay schematic. PABP is added to
purified 20S proteasomes (activated with 0∙03% SDS-AB) or cell lysates and incubated for 2 h. Denaturation with guanidine and capture on
beads is then done simultaneously for 1 h followed by five washes in PBS + 1% BSA + 0∙05% Tween. Primary antibodies for specific proteasome
active site subunits are then added overnight, followed by another five washes. A secondary HRP antibody is then added for 2 h, followed by five
washes. A chemiluminescent substrate is then added for 5–10 min, and luminescence is determined. (B) Proteasome subunit levels were measured
by ProCISE in 62 whole blood and 54 PBMC samples from MM patients and 27 whole blood and 24 PBMC samples from ST patients. CT-L
activity was measured in the same samples using the LLVY-AMC substrate. Data are presented as box and whisker plots with subunit concentra-
tion (ProCISE) or specific activity (LLVY-AMC). Mean specific activity [AMC/protein (lM/lg)] and subunit concentrations [subunit/protein
(ng/lg)] are represented by a horizontal line, and error bars represent minimum and maximum values. (C) Whole blood and PBMC samples
taken 1 h after the first administration of carfilzomib in MM and ST patients (doses: 15–45 mg/m2) were analysed for proteasome subunit activ-
ity by LLVY-AMC and occupancy by ProCISE. Values were normalized to predose values, and data are presented as mean (SEM) relative activ-
ity or occupancy. The dotted line represents the LLOQ for whole blood. (D) MM patients were treated with carfilzomib 15 or 20 mg/m2,
dexamethasone 40 mg and lenalidomide 10, 15, or 25 mg on day 1. Whole blood and PBMC were isolated predose and 1 h after the first dose of
carfilzomib dose was administered. Samples were analysed for proteasome activity and subunit occupancy, as described in panel A. Values are
normalized to predose values, and data are presented as mean (SEM) specific activity or occupancy (N = 2–8 per cohort). LLVY-AMC data are
reproduced from Badros et al (2013) with permission from Nature Publishing Group. (E) MM patients with varying degrees of renal function
were treated with 15 mg/m2 of carfilzomib on day 1. Whole blood and PBMC were isolated predose 1 h after carfilzomib dose administration.
Samples were analysed for proteasome activity and subunit occupancy as described in panel B. Values are normalized to predose values, and data
are presented as mean (SEM) relative activity or occupancy (N = 2–7 per cohort). 1°, primary; 2°, secondary; Ab, antibody; AMC,
aminomethylcoumarin; BSA, bovine serum albumin; CFZ, carfilzomib; CT-L, chymotrypsin-like; D, day; HRP, horseradish peroxidase; LLOQ,
lower limit of quantitation; LLVY, Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin; LMP, low-molecular mass polypeptide; MECL, multicatalytic
endopeptidase complex-like; MM, multiple myeloma; PABP, proteasome active site-binding probe; PBMC, peripheral blood mononuclear cell;
PBS, phosphate buffer solution; SDS-AB, sodium dodecyl sulfate in assay buffer; SEM, standard error of the mean; ST, solid tumour.
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20 mg/m2, albeit at lower levels than LMP7 inhibition (31–
46% inhibition of MECL1 and 22–33% inhibition of LMP2).
At the same doses, there was less than 18% inhibition of the
c20S subunits b2 and b1 in whole blood samples. At a
higher dose (45 mg/m2 administered as a 30-min infusion),
we noted increased occupancy for almost all subunit sites
assessed (Fig 1C). The effect was most prominent for
MECL1 and LMP2; occupancy of b1, however, was not
observed. A statistically significant linear dose-response effect
was seen for occupancy of b5, b2 and MECL1 (P values
were 0∙0044, 0∙0137 and 0∙0432 for the linear trend, respec-
tively).
Carfilzomib has been used in combination with lenalido-
mide and dexamethasone and as a single agent in patients
with relapsed and/or refractory MM and varying degrees of
renal function (Badros et al, 2013; Niesvizky et al, 2013; Sie-
gel et al, 2013). Whole blood and PBMC samples from
patients receiving 15 or 20 mg/m2 of carfilzomib with 40 mg
of dexamethasone and 10, 15 or 25 mg of lenalidomide
(study PX-171-006) were taken 1 h after the first dose of
carfilzomib and analysed for active site activity and occu-
pancy. Levels of active site occupancy were similar in patients
receiving carfilzomib in combination with varying doses of
lenalidomide (Fig 1D). No effect from the co-administration
of lenalidomide was noted at later time points in cycle 1 or
at the beginning of cycle 2 (data not shown). In addition,
active site occupancy was similar when patients treated with
15 mg/m2 of carfilzomib were stratified based on renal func-
tion status (study PX-171-005) and was consistent with
results previously reported using the LLVY-AMC assay
(Fig 1E) (Badros et al, 2013). Taken together, these data
demonstrate that carfilzomib induces consistent and potent
occupancy of multiple proteasomal active sites in MM
patients, regardless of concomitant drug administration or
renal function.
Sustained proteasome inhibition after repeated
carfilzomib administration
As carfilzomib selectively and irreversibly binds to its target
(Demo et al, 2007), we assessed the duration of subunit
occupancy and recovery of proteasome activity following its
use. Whole blood and PBMC samples were analysed from
patients from multiple studies both prior to and 1 h after
receiving carfilzomib on days 1, 2 and 8 of cycle 1 and on
day 1 of cycle 2. Consistent with results from animal studies
(Demo et al, 2007), we observed cumulative and sustained
subunit occupancy in whole blood samples that was most
evident for b2 and b5 (Fig 2A). In PBMCs, modest recovery
was seen 24 h after the first dose (day 2, predose), but
unbound subunit levels were lower than pretreatment values
(see Fig 2A). Following the second dose of carfilzomib, a
slight increase in occupancy was observed across all i20S
subunits (day 2, 1 h). Recovery following a 5-day non-dos-
ing period (day 8, predose) was more prominent than after
a 24-h period (day 2, predose), but full recovery was not
achieved. By the start of cycle 2 (cycle 2, predose), complete
or near-complete recovery was noted in PBMCs for all three
i20S active sites at doses below 36 mg/m2. These results, in
which data for each dose level were pooled across studies,
are similar to those previously reported using the LLVY-
AMC assay in patients treated with carfilzomib, lenalidomide
and dexamethasone from PX-171-006 (Niesvizky et al,
2013). Our findings suggest that the addition of lenalido-
mide and dexamethasone to carfilzomib treatment does not
impact the pharmacodynamics of carfilzomib-mediated pro-
teasome inhibition. In patients receiving 45 mg/m2 of carfil-
zomib, minimal recovery was observed between day 8 and
the start of cycle 2; it should be noted, however, that rela-
tively few patients (range, 3–9) were analysed at this dose
level.
In study PX-171-007, patients were dose-escalated from
20 mg/m2 to a target dose that ranged from 27 to 56 mg/m2
beginning on day 8 of cycle 1. As near complete recovery of
proteasome activity and subunit levels in PBMC was
observed by the beginning of cycle 2 (cycle 2, predose), we
compared the level of individual i20S subunit occupancy on
cycle 2, day 1 with pretreatment values. Results from Pro-
CISE showed that all doses resulted in similar and potent
increases in LMP7 occupancy, regardless of whether carfil-
zomib was administered as a 2- to 10-min infusion or as a
30-min infusion, while a dose-dependent increase in MECL1
and LMP2 occupancy was observed at doses of up to
45 mg/m2 (Figure S3). At a dose of 56 mg/m2 (the maxi-
mum tolerated dose in patients with MM when infused over
30 min), carfilzomib produces near-complete LMP7 inhibi-
tion (i.e. at the limit of quantitation of the assay) and was
bound to, on average, more than 79% of all i20S active
sites.
We next determined whether the levels of proteasome
inhibition detected in whole blood and PBMC samples were
representative of target inhibition in tumour cells. As an
optional correlative study, CD138+ tumour cells were iso-
lated from bone marrow aspirates taken during screening
and on cycle 1, day 2, and levels of b5, LMP7 and MECL1
were assessed. Following administration of carfilzomib at a
dose of 15 or 20 mg/m2, we observed a statistically signifi-
cant (>95%) reduction in CT-L activity as assessed by
LLVY-AMC (P < 0∙001). More moderate but still statisti-
cally significant reductions were seen at the b5, LMP7 and
MECL1 active sites [reductions of 52% (P < 0∙05), 58%
(P < 0∙01) and 50% (P < 0∙05), respectively] (Fig 2B).
Intriguingly, we also observed that the i20S accounts for
nearly 75% of the proteasome activity in these MM tumour
cells (Table II). Not all samples could be tested in both
assays because of the limited sample volume, which may
account for discrepancies in the inhibition levels measured
by LLVY-AMC and by ProCISE. Despite the limitations of
this analysis, these data suggest that the use of carfilzomib
results in inhibition lasting more than 48 h and that pro-
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Fig 2. Repeat administration of carfilzomib
results in sustained proteasome inhibition. (A)
Patients received carfilzomib at 15, 20, 36 or
45 mg/m2 on days 1, 2, 8, D9, 15 and 16 of a
28-day cycle. Whole blood and PBMC samples
were taken prior to and 1 h after administra-
tion on days 1, 2 and 8 of cycle 1 and day 1 of
cycle 2. Samples were analysed for proteasome
activity and subunit occupancy as described in
Fig 1 and were normalized to cycle 1, day 1
predose values. Data are presented as mean
(SEM) relative specific activity or occupancy.
(B) Bone marrow samples from MM patients
were taken during baseline screening and/or on
cycle 1, day 2, 1 to 4 h after the second dose
of carfilzomib. CD138+ cells and samples were
analysed for proteasome activity and subunit
occupancy. Data are presented as mean
(SEM) relative activity or subunit concentra-
tion. *P < 0∙001; **P < 0∙01; ***P < 0∙05 by a
t-test. C, cycle; CT-L, chymotrypsin-like; D,
day; AMC, aminomethylcoumarin; LMP,
low-molecular mass polypeptide; MECL, multi-
catalytic endopeptidase complex-like; MM,
multiple myeloma; PBMC, peripheral blood
mononuclear cell; SEM, standard error of the
mean.
Table II. CT-L Activity and Proteasome Subunit Levels in Baseline Primary Myeloma Cells and Multiple Myeloma Cell Lines.














5 (1–13) 11∙3  2∙8 0∙9  0∙1 2∙6  0∙4 74∙3
Number of samples 29 18 22
AMC, 7-amino-4-methylcoumarin; CT-L, chymotrypsin-like; LMP, low-molecular mass protein.
*Bone marrow aspirates were collected from patients in trials PX-171-003, PX-171-004 and PX-171-005 prior to carfilzomib dosing and sorted
into CD138+ and CD138 populations. CD138+ samples were analysed for proteasome activity and subunit occupancy as described in Fig. 1.
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teasome inhibition in tumour cells is similar to that
observed in PBMC samples.
Correlation between proteasome inhibition and response
To determine whether the level of proteasome inhibition
achieved with carfilzomib treatment corresponded to clinical
response rates, samples from 29 patients with MM who
received the highest tolerated dose (20/56 mg/m2 in PX-171-
007) and the lowest administered dose of carfilzomib (15 or
15/20 mg/m2 in PX-171-005) were compared (Fig 3A;
Table III). During the first 2 days of carfilzomib treatment
(15–20 mg/m2), no statistically significant differences in
levels of proteasome inhibition were observed. When the
dose was escalated to 56 mg/m2 on cycle 1, day 8 for patients
in PX-171-007, significantly greater active site occupancy was
observed across all three i20S subunits in patients who
received the higher dose compared with patients in PX-171-
005 who continued to receive the lower dose. In patients
receiving 56 mg/m2, carfilzomib binding to LMP7, MECL1
and LMP2 was increased by 7∙9%, 23∙1% and 33∙6%, respec-
tively, relative to patients receiving 15 or 20 mg/m2 (see
Fig 3A and B; P < 0∙05, P <0∙001 and P < 0∙01, respec-
tively). Increased occupancy of LMP2 at the beginning of C2
was also noted in the high-dose group. Strikingly, 64% of
patients in this analysis who received the higher dose had a
clinical response compared with only 11% of patients receiv-
ing a lower dose (see Table III). These data suggest a rela-
tionship between carfilzomib dose, proteasome inhibition
and patient response, in which greater occupancy of multiple
immunoproteasome subunits is correlated with an increased
likelihood of achieving a clinical response.
Discussion
Proteasome inhibition is a validated strategy for the treat-
ment of B-cell neoplasms, but limitations in conventional
assays have prevented pharmacodynamic-based correlative
studies of drug action. We describe here the clinical valida-
tion and application of ProCISE, a novel assay for monitor-
ing proteasome inhibition via active site occupancy in
patient samples that circumvents these limitations and
enables a more complete profile of drug action. ProCISE
allows for quantitative monitoring of drug binding to all six
proteasomal catalytic subunits in cells derived from patient
samples, such as PBMC and primary tumour cells. By mea-
suring the binding of each individual subunit, we are able to
monitor specific active site inhibition in tumour cells
(CD138+ myeloma cells) that express the c20S and i20S. This
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Fig 3. Immunoproteasome subunit inhibition
is correlated with activity in multiple myeloma.
(A) Proteasome inhibition in PBMC samples
was measured as described in Fig 1. Patients
were stratified according to carfilzomib dose:
either 20/56 mg/m2 from PX-171-007 or 15
and 15/20 mg/m2 from PX-171-005. Values
(relative to cycle 1, day 1 predose) are pre-
sented as mean (SEM) relative subunit con-
centration or specific activity. The shaded area
represents the time points in which the dose
was stepped up to 56 mg/m2 for PX-171-007
patients or 20 mg/m2 for some PX-171-005
patients. *P < 0∙05; **P < 0∙01; ***P < 0∙001
by a t-test. (B) Data from panel A at cycle 1,
day 8 1-h time point. #P < 0∙05; ##P < 0∙001;
###P < 0∙01; by a t-test. C, cycle; CT-L, chy-
motrypsin-like; D, day; LMP, low-molecular
mass polypeptide; MECL, multicatalytic
endopeptidase complex-like; PBMC, peripheral
blood mononuclear cell; SEM, standard error
of the mean.
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compounds that are selective for individual 20S active sites
(Muchamuel et al, 2009). As existing substrate-based assays
are unable to differentiate between c20S and i20S enzymatic
activities for any of the subunits, ProCISE currently
represents the only known method to monitor the inhibition
of individual subunits.
Previously, the pharmacodynamic profile of carfilzomib
was assessed in vitro using the ProCISE assay (Parlati et al,
2009). In tumour cell lines, carfilzomib has been shown to
have equivalent and potent activity against both b5 and
LMP7 and to be at least 10-fold less potent against the other
subunits of the c20S and i20S (Parlati et al, 2009). In the
current analysis, we verified the potency of carfilzomib for
CT-L active sites ex vivo and have extended previous findings
in samples derived from carfilzomib-treated patients. In
patients treated with doses ≥15 mg/m2, on average an inhibi-
tion rate of greater than 83% was achieved in b5 and LMP7.
As in the in vitro studies, there was a correspondence
between values derived with ProCISE and those derived from
the enzymatic assay for CT-L activity. Slightly greater inhibi-
tion was observed in whole blood with the enzymatic assay
compared with ProCISE, probably due to a quenching effect
of the blood matrix – possibly haemoglobin – on the enzy-
matic activity and the presence of LMP7 in erythrocytes and
PBMCs (whole blood samples were not depleted of PBMCs
prior to the assay). However, there was a significant correla-
tion between inhibition of CT-L activity and ProCISE in
whole blood and PBMCs for the aggregate of paired samples
(Table SII). Inhibition levels were also equivalent in patients
with MM receiving 20 mg/m2 carfilzomib as a 2- to 10-min
or 30-min infusion, which is consistent with results reported
in animals (Yang et al, 2011). It is noteworthy that the over-
all level of CT-L inhibition seen with carfilzomib is higher
than the 65–70% inhibition rate reported in bortezomib-trea-
ted patients (Orlowski et al, 2002; Papandreou et al, 2004;
Moreau et al, 2008). Using ProCISE, we also demonstrated
that the administration of carfilzomib inhibits proteasome
subunit occupancy in bone marrow–derived tumour cells. It
is possible that the small sample size (n = 5) accounts for
discrepancies seen between inhibition levels of CT-L activity
assessed by LLVY-AMC and by b5 and LMP7 occupancy
assessed by ProCISE; however, we cannot rule out altered
binding properties within tumour cells. Nevertheless, these
data represent the first known direct correlation between
proteasome inhibition in blood samples to that in tumour
cells in patients with MM.
Clinical trials have demonstrated that carfilzomib and
bortezomib are clinically active regardless of the degree of
renal insufficiency in patients (Jagannath et al, 2005; San-
Miguel et al, 2008; Badros et al, 2013). Consistent with this,
we found that carfilzomib induces consistent and potent inhi-
bition of multiple proteasomal active sites in MM patients,
regardless of patient renal function. In addition, we found that
concomitant drug administration did not affect levels of active
site occupancy, as assessed in patients receiving carfilzomib in
combination with varying doses of lenalidomide. To our
knowledge, this is the first time the subunit-specific pharma-
codynamic activity of a proteasome inhibitor has been charac-
terized in MM patients with renal impairment or concomitant
drug administration, providing additional information on the
activity of this class of agents in a variety of clinical settings.
In rodents, proteasome activity following treatment with
carfilzomib recovers with a half-life of approximately 24 h in
tissues (e.g. adrenal and bone marrow), but prolonged inhibi-
tion was observed in whole blood for which recovery is depen-
dent on red blood cell turnover (Demo et al, 2007). Little to
no recovery of proteasome activity was observed in whole
blood following the administration of carfilzomib, which is
consistent with our preclinical results. Somewhat surprisingly,
recovery of activity in PBMCs was slower than predicted based
on animal data. Minimal recovery of proteasome activity was
observed 24 h after the first dose, and incomplete recovery
was seen after the 5-day non-dosing period during the first
week of treatment. This effect is unlikely to be due to pro-
longed exposure, because carfilzomib is rapidly cleared from
the plasma (O’Connor et al, 2009). Rather, these data demon-
strate that carfilzomib results in proteasome inhibition that
lasts at least 48 h and suggests that PBMCs have an altered
rate of proteasome recovery relative to other cell types. In
contrast, a 50% recovery of activity was seen 12 h after the
administration of bortezomib, with full recovery occurring
36 h after dosing (Hellmann et al, 2011). We hypothesize that
differences in proteasome recovery between the two drugs
may be due to the irreversible binding of carfilzomib in con-
trast to the reversible binding of bortezomib to the protea-
some (Demo et al, 2007).
Interestingly, administration of carfilzomib resulted in
increased occupancy of MECL1 and LMP2 in PBMCs but
not of b1 and b2 in whole blood. This finding was unex-
pected given the weak potency of carfilzomib ex vivo against
non–CT-L subunits in whole blood and PBMCs. Levels of
MECL1 and LMP2 inhibition have a statistically significant
Table III. Clinical response in patients receiving the highest tolerated



















PD, progressive disease; PR, partial response; SD, stable disease.
*Patients received carfilzomib at a dose of 15 or 20 mg/m2 on days 1
and 2 and a target dose of 56 or 20 mg/m2 on days 8, 9, 15 and 16
in trials PX-171-007 and PX-171-005, respectively. Some patients in
PX-171-005 did not step up to their target dose (e.g. from 15 to
20 mg/m2) and continued to receive 15 mg/m2. Patient responses
were determined using International Myeloma Working Group crite-
ria (Badros et al, 2013; Papadopoulos et al, 2013).
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linear dose effect in which higher doses of carfilzomib lead
to greater inhibition. While inhibition of LMP2 in samples
from bortezomib-treated patients has previously been
reported (Kraus et al, 2007; Arastu-Kapur et al, 2011), this is
the first known report of MECL1 inhibition by a proteasome
inhibitor in patients. The mechanism of selective LMP2 and
MECL1 inhibition by carfilzomib relative to b1 and b2 inhi-
bition remains to be defined. Although data from our group
demonstrated that combined inhibition of b5 and LMP7 was
necessary and sufficient to induce apoptosis in myeloma cells
in vitro (Parlati et al, 2009), several studies have postulated a
role for the other active sites of the i20S in anti-myeloma
responses. Kuhn et al (2009) have shown that LMP2-selective
inhibitors can induce myeloma cell death, and multiple
reports have demonstrated synergistic tumour cell killing
with carfilzomib or bortezomib and either an LMP2/b1 or
MECL1/b2 selective inhibitor (Britton et al, 2009; Mirabella
et al, 2011). It is possible that the simultaneous inhibition of
multiple i20S subunits contributes to the potent anti-tumour
activity of carfilzomib in patients with MM, including
patients that are refractory to bortezomib (Siegel et al, 2012;
Vij et al, 2012a), particularly given that approximately 75%
of the proteasomes in isolated myeloma cells are i20S.
Importantly, we observed a relationship between carfil-
zomib dose, i20S inhibition, and clinical response in patients
with MM. Patients receiving a dose of 56 mg/m2 of carfil-
zomib beginning on day 8 showed significantly greater inhibi-
tion of all three i20S subunits compared with patients who
received 15 or 20 mg/m2 of carfilzomib. Given that near-com-
plete inhibition of LMP7 was noted even at 15 mg/m2, higher
doses of carfilzomib resulted in small differences in LMP7
inhibition. However, significantly greater levels of inhibition
of both LMP2 and MECL1 were noted in patients receiving
56 mg/m2 of carfilzomib compared with those receiving 15 or
20 mg/m2 (i.e. cycle 1, day 8). At cycle 2, day 1, LMP2 inhibi-
tion remained significantly different between the two groups,
reaffirming that higher doses of carfilzomib led to greater i20S
inhibition. The difference observed in MECL1 at cycle 2, day 1
is probably not statistically significant because of the small
sample size (n = 4) in the 20/56-mg/m2 cohort. Of the
patients analysed for pharmacodynamics, 64% of patients
receiving 20/56 mg/m2 achieved a clinical response compared
with only 11% of patients receiving 15 or 20 mg/m2. While
these samples were derived from different patient populations,
both trials enrolled patients with relapsed and/or refractory
MM who had been treated with at least two prior regimens.
Overall, these data suggest that higher doses of carfilzomib
lead to greater levels of i20S inhibition, resulting in improved
clinical responses in patients with MM. Although these data
are derived from small numbers of patients and should be ver-
ified in larger, randomized trials, they do support previous
findings of a dose-response relationship seen with earlier phase
II trials of single-agent carfilzomib (Squifflet et al, 2011).
In summary, we present the first clinical validation and
application of the ProCISE assay. Administration of
carfilzomib results in potent and prolonged inhibition of
multiple proteasome active sites in patients with MM. In
patients with MM, there is a dose-dependent relationship
between pharmacodynamic inhibition and anti-tumour
response following carfilzomib treatment. It is worth noting
that the ProCISE assay can also be used to assess and com-
pare the activity of other proteasome inhibitors besides
carfilzomib (Parlati et al, 2009), as ProCISE is not treatment-
specific. Therefore, ProCISE represents a potentially valuable
new tool for measuring the activity of proteasome inhibitors
in clinical trials and can be used to relate drug action to
patient outcomes.
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